哌拉西林-他唑巴坦在松质骨和皮质骨组织中的渗透情况。
Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues.
作者信息
Incavo S J, Ronchetti P J, Choi J H, Wu H, Kinzig M, Sörgel F
机构信息
University Orthopaedics, University of Vermont, Burlington 05405.
出版信息
Antimicrob Agents Chemother. 1994 Apr;38(4):905-7. doi: 10.1128/AAC.38.4.905.
Abstract
The penetration characteristics of piperacillin-tazobactam into cortical and cancellous bone tissues were investigated in 10 patients undergoing total hip replacement. The concentration ratios of piperacillin/tazobactam were 9.4 +/- 1.8 in cancellous bone tissue and 8.0 +/- 2.2 in cortical bone tissue, which were close to the 8:1 ratio of drugs administered. The mean ratios of drug concentrations in bone and plasma for cancellous and cortical tissue were 23 and 18%, respectively, for piperacillin and 26 and 22%, respectively, for tazobactam. The concentrations of tazobactam achieved are sufficient to exert anti-beta-lactamase activity and supportive of clinical trials involving bone and joint infections, including those caused by beta-lactamase-producing pathogens.
摘要
在10例接受全髋关节置换术的患者中，研究了哌拉西林-他唑巴坦在皮质骨和松质骨组织中的渗透特性。哌拉西林/他唑巴坦在松质骨组织中的浓度比为9.4±1.8，在皮质骨组织中的浓度比为8.0±2.2，接近给药药物的8:1比例。对于哌拉西林，松质骨和皮质组织中骨与血浆药物浓度的平均比值分别为23%和18%，对于他唑巴坦分别为26%和22%。所达到的他唑巴坦浓度足以发挥抗β-内酰胺酶活性，并支持涉及骨和关节感染（包括由产β-内酰胺酶病原体引起的感染）的临床试验。
相似文献
1
Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues.哌拉西林-他唑巴坦在松质骨和皮质骨组织中的渗透情况。
Antimicrob Agents Chemother. 1994 Apr;38(4):905-7. doi: 10.1128/AAC.38.4.905.
2
Penetration of piperacillin/tazobactam (4 g/500 mg) into synovial tissue.哌拉西林/他唑巴坦（4克/500毫克）在滑膜组织中的渗透情况。
J Chemother. 2002 Feb;14(1):54-8. doi: 10.1179/joc.2002.14.1.54.
3
Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.哌拉西林-他唑巴坦两种给药方案的药代动力学和药效学评价。
Pharmacotherapy. 2002 May;22(5):569-77. doi: 10.1592/phco.22.8.569.33209.
4
Pharmacokinetic characteristics of piperacillin/tazobactam.哌拉西林/他唑巴坦的药代动力学特征。
Intensive Care Med. 1994 Jul;20 Suppl 3:S14-20. doi: 10.1007/BF01745246.
5
6
Concentrations of piperacillin-tazobactam in human jaw and hip bone.哌拉西林-他唑巴坦在人颌骨和髋骨中的浓度。
J Craniomaxillofac Surg. 2008 Dec;36(8):468-72. doi: 10.1016/j.jcms.2008.06.003. Epub 2008 Sep 9.
7
Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.使用蒙特卡洛分析对持续输注哌拉西林/他唑巴坦针对铜绿假单胞菌的药效学特征进行分析。
Diagn Microbiol Infect Dis. 2002 Sep;44(1):51-7. doi: 10.1016/s0732-8893(02)00416-9.
8
The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam.哌拉西林/他唑巴坦的化学、药代动力学及组织分布
J Antimicrob Chemother. 1993 Jan;31 Suppl A:39-60. doi: 10.1093/jac/31.suppl_a.39.
9
Penetration of piperacillin-tazobactam into bronchial secretions after multiple doses to intensive care patients.多次给药后哌拉西林-他唑巴坦在重症监护患者支气管分泌物中的渗透情况。
Antimicrob Agents Chemother. 1994 Dec;38(12):2780-4. doi: 10.1128/AAC.38.12.2780.
10
Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery.结直肠手术患者中他唑巴坦和哌拉西林的药代动力学及组织穿透性
Antimicrob Agents Chemother. 1992 Sep;36(9):1997-2004. doi: 10.1128/AAC.36.9.1997.
引用本文的文献
1
Piperacillin Steady State Concentrations in Target Tissues Relevant for PJI Treatment-A Randomized Porcine Microdialysis Study Comparing Continuous Infusion with Intermittent Short-Term Infusion.哌拉西林在与假体周围感染（PJI）治疗相关的靶组织中的稳态浓度——一项比较持续输注与间歇性短期输注的随机猪微透析研究。
Antibiotics (Basel). 2023 Mar 14;12(3):577. doi: 10.3390/antibiotics12030577.
2
Intermittent Short-Term Infusion vs. Continuous Infusion of Piperacillin: Steady State Concentrations in Porcine Cervical Spine Tissue Evaluated by Microdialysis.哌拉西林间歇短期输注与持续输注的比较：通过微透析评估猪颈椎组织中的稳态浓度
Antibiotics (Basel). 2022 Jul 7;11(7):910. doi: 10.3390/antibiotics11070910.
3
The association between radiological spreading pattern and clinical outcomes in necrotizing external otitis.坏死性外耳道炎的放射学扩散模式与临床结局之间的关联。
J Otol. 2022 Jul;17(3):156-163. doi: 10.1016/j.joto.2022.05.002. Epub 2022 Jun 3.
4
Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.抗感染药物剂量的药代动力学和药效学原理。
Clin Ther. 2016 Sep;38(9):1930-47. doi: 10.1016/j.clinthera.2016.06.015. Epub 2016 Jul 20.
5
Systemic antibiotic therapy for chronic osteomyelitis in adults.成人慢性骨髓炎的全身抗生素治疗。
Clin Infect Dis. 2012 Feb 1;54(3):393-407. doi: 10.1093/cid/cir842. Epub 2011 Dec 12.
6
Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.抗菌药物在骨组织中的渗透：药代动力学、药效学及生物分析学考量
Clin Pharmacokinet. 2009;48(2):89-124. doi: 10.2165/00003088-200948020-00002.
7
Adjuvant arthritis-induced changes on ampicillin binding in serum and tissues under the influence of non-steroidal anti-inflammatory drugs in rats.大鼠中，非甾体抗炎药影响下佐剂性关节炎诱导的血清和组织中氨苄青霉素结合的变化。
Eur J Drug Metab Pharmacokinet. 2005 Oct-Dec;30(4):235-41. doi: 10.1007/BF03190626.
8
Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.哌拉西林/他唑巴坦：其在治疗细菌感染中的应用最新综述
Drugs. 1999 May;57(5):805-43. doi: 10.2165/00003495-199957050-00017.
9
Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients.哌拉西林和他唑巴坦在脑积水患者脑室脑脊液中的动力学
Antimicrob Agents Chemother. 1997 May;41(5):987-91. doi: 10.1128/AAC.41.5.987.
本文引用的文献
1
The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam.哌拉西林/他唑巴坦的化学、药代动力学及组织分布
J Antimicrob Chemother. 1993 Jan;31 Suppl A:39-60. doi: 10.1093/jac/31.suppl_a.39.
2
A problem in the interpretation of beta-lactam antibiotic levels in tissues.β-内酰胺类抗生素在组织中水平的解读问题。
J Antimicrob Chemother. 1983 Sep;12(3):281-4. doi: 10.1093/jac/12.3.281.
3
Piperacillin therapy for serious bacterial infections.
Am J Med. 1980 Aug;69(2):255-61. doi: 10.1016/0002-9343(80)90386-1.
4
Piperacillin sodium: antibacterial spectrum, pharmacokinetics, clinical efficacy, and adverse reactions.哌拉西林钠：抗菌谱、药代动力学、临床疗效及不良反应。
Pharmacotherapy. 1982 Nov-Dec;2(6):287-99. doi: 10.1002/j.1875-9114.1982.tb03202.x.
5
Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.β-内酰胺酶抑制剂YTR 830、克拉维酸钠和舒巴坦与阿莫西林或氨苄西林联合使用的比较活性。
Antimicrob Agents Chemother. 1984 Oct;26(4):580-2. doi: 10.1128/AAC.26.4.580.
6
Concentrations of ticarcillin and clavulanic acid in human bone after prophylactic administration of 5.2 g of timentin.预防性给予5.2克替卡西林克拉维酸后人体骨骼中替卡西林和克拉维酸的浓度。
Antimicrob Agents Chemother. 1987 Jun;31(6):935-9. doi: 10.1128/AAC.31.6.935.
7
Penetration of amoxycillin and clavulanic acid into bone.
Chemotherapy. 1986;32(3):185-91. doi: 10.1159/000238414.
8
Penetration of amoxycillin/clavulanate into human bone.
J Antimicrob Chemother. 1989 Nov;24 Suppl B:93-100. doi: 10.1093/jac/24.suppl_b.93.
9
Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains.
Diagn Microbiol Infect Dis. 1989 Nov-Dec;12(6):489-94.
10
Pharmacokinetics of antibiotics in tissues and tissue fluids: a review.抗生素在组织和组织液中的药代动力学：综述
Scand J Infect Dis Suppl. 1990;74:23-33.
Zotero 插件